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Background: Pain tolerance is subject to considerable inter-individual variation, which may be influenced by a
number of genetic and non-genetic factors. The mu, delta and kappa opioid receptors play a role in pain
perception and are thought to mediate different pain modalities. The aim of this study was to explore associations
between pain thresholds and gender and genetic variants in the three opioid receptor genes (OPRM, OPRD and
OPRK). Experimental multi-modal pain data from previously published studies carried out in healthy Caucasian
volunteers were used in order to limit the number of confounders to the study outcome. Data on thermal skin pain
(n=36), muscle pressure pain (n=31) and mechanical visceral pain (n=50)) tolerance thresholds were included.
Results: Nineteen genetic polymorphisms were included in linear regression modeling. Males were found to
tolerate higher thermal and muscle pressure pain than females (p=0.003 and 0.02). Thirty four percent of variability
in thermal skin pain was accounted for by a model consisting of OPRK rs6473799 and gender. This finding was just
outside significance when correction for multiple testing was applied. Variability in muscle pressure pain tolerance
was associated with OPRK rs7016778 and rs7824175. These SNPs accounted for 43% of variability in muscle pressure
pain sensitivity and these findings remained significant after adjustment for multiple testing. No association was
found with mechanical visceral pain.
Conclusion: This is a preliminary and hypothesis generating study due to the relatively small study size. However,
significant association between the opioid receptor genes and experimental pain sensitivity supports the influence
of genetic variability in pain perception. These findings may be used to generate hypotheses for testing in larger
clinical trials of patients with painful conditions.
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Sensitivity to pain is subject to significant inter-individual
variation. There has been growing interest in identifying
the possible factors which might contribute to this vari-
ation. A significant confounder in the study of nociception
in clinical practice is the existence of a number of different
pain modalities including thermal, muscle pressure and
visceral pain. Many clinically relevant pains such as cancer
pain are likely to represent a mixture of these modalities.
It is difficult, if not impossible to differentiate pain data
from studies involving patients with painful disease in
terms of pain perception modalities. Furthermore, noci-* Correspondence: h.sato@imperial.ac.uk
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reproduction in any medium, provided the orception in patients with disease is influenced by a number
of other factors including psychological state, concomitant
medications, co-morbidities and disease treatment. There-
fore studies which are carried out under experimental
conditions in otherwise healthy volunteers may provide a
“cleaner” platform from which to unpick inter-individual
variation in pain perception.
Animal, familial and twin studies have provided con-
vincing evidence of association between nociception and
genetic variability. Painful conditions which appear to
have some element of heritability include back pain, dys-
menorrhoea, sciatica, musculoskeletal pain, spinal pain
and irritable bowel syndrome [1-3]. Data from twin
studies suggest up to 60% heritability of response to ex-
perimental painful stimuli [4,5]. There are also a number
of heritable pain conditions in chronic non-cancer paind. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Allele carriage frequencies in study population
(n=50)










rs6912029 Exon 1 Gln-His G 50 100
T 1 2
rs1799971 Exon 1 Asn-Asp A 49 98
G 8 16
rs563649 Intron 1 C 50 100
T 9 18
rs9479757 Intron 2 G 12 24
A 49 98




rs10504151 Intron 2 - T 50 100
C 9 18
rs7836120 Intron 2 - A 49 98
G 20 40
rs6473799 Intron 2 - T 45 90
C 24 48
rs1365098 Intron 2 - G 43 86
T 30 60
rs7016778 Intron 2 - T 50 100
A 15 30
rs7824175 Intron 3 - G 47 94
C 12 24
rs16918875 Exon 4 Val-Val C 50 100
T 4 8
rs963549 3UTR - G 47 94
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been identified [6]. One example includes the SCN9A
gene, which codes for a peripheral sodium channel
NaV1.7. Variation in this gene is associated with either a
complete inability to sense pain or extreme pain disor-
ders such as erythermalgia and paroxysmal extreme pain
disorder [7,8]. Such disorders however are extremely
rare. Although a number of “pain genes” have been
proposed and analysed [9], to date the results of genetic
association studies in clinically relevant painful condi-
tions have been inconsistent, with little applicability to
clinical practice. In most studies only one or a few
polymorphisms in each possible pain gene have been
analysed.
The mu, delta and kappa opioid receptors are all
involved in nociception and are thus obvious can-
didates for a genetic association study. Recent data
have suggested that these opioid receptors may be
distinct in both physical location and also mode of
pain transmission [10]. Only one candidate gene asso-
ciation study in experimental pain has examined gen-
etic variation across all three opioid receptor genes
[11]. That study was limited to women and explored
only association with pressure pain. Furthermore only
one polymorphism from OPRD and OPRK were
included. The aim of this study was to investigate the
association between multiple genetic variations (poly-
morphisms) across the mu, delta and kappa opioid
receptor genes (OPRM, OPRD and OPRK respectively)
and variability in sensitivity to multi-modal, multi-
tissue experimental pain stimulations in healthy vol-
unteers. Gender and age were also included in the
statistical modeling as these factors are known to
influence pain sensitivity [12,13].A 18 36
Opioid receptor
delta (OPRD)
rs1042114 Exon 1 Cys-Phe G 11 22
T 50 100
rs533123 Intron 1 - G 15 30
A 48 96
rs419335 Intron 1 - A 42 84
G 23 46
rs2236857 Intron 1 - T 46 92
C 15 30
rs2234917 Exon 3 Gly-Gly C 34 68
T 40 80Results
Study subjects
50 healthy Caucasian, opioid-naïve volunteers were in-
cluded in this analysis; 22 female, 28 male, median age
26 years (range 19–48 years). Pain tolerance threshold me-
dian for thermal heat pain was 46.6°C (range 40.8-52.1),
muscle pressure pain 39.4 kPa (range 25.5-76.4) and me-
chanical visceral pain 18.4 ml (5.2-67.8).
The intra-study reliability testing between baseline
pain sensitivity scores demonstrated Cronbach’s α scores
>0.7 for all pain modalities, confirming reliability. The
average of the three baseline pain sensitivity scores were
used as the outcome variables in stepwise linear regres-
sion analyses to explore associations with genetic factors
and gender.
All SNPs (single nucleotide polymorphisms) were in
Hardy-Weinberg equilibrium. The allele carriage frequen-
cies in the study population are detailed in Table 1.Pain and gender
There was a significant association between gender and
both thermal skin pain and muscle pressure pain. Males
had higher pain thresholds in both thermal skin pain
(male; n=14, average 48.4 +/− 2.5°C vs. female; n=22, ave-
rage 46.7 +/− 2.5°C, p=0.003), (Figure 1a) and muscle
Figure 1 Pain and gender. a) Males (n=14, 48.4°C) have higher
thermal skin pain thresholds than females (n=22, 46.7°C) (p=0.003).
Line demonstrates mean values. b) Males (n=20, 47.4 kPa) have
higher muscle pressure pain thresholds than females (n=11. 35.1 kPa)
(p=0.02). Line demonstrates median values.
Table 2 Factors entered into the multivariate models
(p<0.1 on univariate regression analysis) for thermal skin
pain and muscle pressure pain
p-values
Thermal skin pain Gender 0.003
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76.4) vs. female; n= 11, median 33.5 kPa (range 25.5-49.7),
p=0.02), (Figure 1b). Gender was not associated with vari-
ability in mechanical visceral pain.Pain and age
There was a significant association between muscle
pressure pain and age (p=0.01). There was no associ-
ation between age and thermal skin pain and mechanical
visceral pain.Pain and the opioid receptors polymorphisms
Thermal skin pain
Six predictor variables (gender, 3 OPRK SNPs and 2
OPRM SNPs) were significant at the level of 10% (p<0.1)
on univariate analysis for thermal skin pain and these were
entered into the multivariate models (Table 2 and
Figure 2). Thirty-four percent of variability in sensitivity to
thermal heat pain was associated with OPRK rs6473799
and gender on multivariate regression (Table 3).When the Bonferroni adjustment for multiple testing
was applied (p<0.008 was significant for thermal skin
pain), these associations were just outside significance.Muscle pressure pain
Five predictor variables (gender, age, and 3 OPRK SNPs)
were significant at the level of 10% (p<0.1) on univariate
analysis for muscle pressure pain and these were entered
into the multivariate models (Table 2 and Figure 3).
OPRK rs7016778 and rs7824175 were retained as inde-
pendent predictors of muscle pain sensitivity in multi-
variate regression analysis. These findings remained
significant after Bonferroni correction for multiple test-
ing (adjusted p<0.01 was significant for muscle pressure
pain). Together these SNPs accounted for 43% of vari-
ability in sensitivity to muscle pressure pain (Table 3). In
our data these SNPs are not in strong linkage disequi-
librium (LD) (r2=0.03, LOD=0.55), mirroring the LD
parameters from the HapMap Project [14]. Age and gen-
der were not retained as significant predictors of muscle
pressure pain in regression analysis.Mechanical visceral pain
This parameter was not significantly associated with
gender or any polymorphisms in OPRM, OPRD or OPRK.
Haplotype analysis did not add to the associations
described.Discussion
This is the first pain genetics study in which multiple
polymorphisms across all three opioid receptor genes
(OPRM, OPRD, OPRK) were considered together to
build a predictive model of nociception. These data sug-
gest that genetic factors and gender account for 34-43%
of variability in thermal and mechanical pain sensitivity.
Figure 2 Association between OPRK rs643799 and variability in
thermal skin pain thresholds (univariate analysis). Carriers of
OPRK rs643799C allele (genotype CC / CT, n=18, 47.9+/−2.7°C) have
lower thermal pain thresholds than non-carriers (genotype TT, n=18,
45.5+/−2.3°C), p=0.009. Line demonstrates mean values.
Sato et al. Molecular Pain 2013, 9:20 Page 4 of 9
http://www.molecularpain.com/content/9/1/20Opioid receptor genes and pain
As opioid receptors are key players in the nociceptive
pathway, the genes coding for these receptors were
chosen as candidates in this study. Most previous
genetic association studies in this area have focused on
OPRM. A number of different polymorphisms across
OPRM have been associated with variability in pain
sensitivity but there have been a number of inconsisten-
cies between studies [15] and the clinical significance of
the findings is unclear In humans there is much less data
regarding the influence of polymorphisms in OPRD and
OPRK in pain sensitivity. In a study of 500 normal
participants, a polymorphism in OPRD rs2234918 was
associated with a gender specific difference in thermal
pain sensitivity [16]. However OPRD haplotype analysis in
a similar study by the same researchers did not show any
association [17]. Although one study in mice found an
association between OPRK and morphine antinociceptionTable 3 Multivariate regression models of factors predictive o




OPRK rs6473799 (CC/CT vs TT)
Muscle pressure pain (N=31)
Model R square
1 0.264 OPRK rs7016778 (AA/AT vs TT)
2 0.427 OPRK rs7016778 (AA/AT vs TT)
OPRK rs7824175 (CC/CG vs GG)
B represents the regression coefficient. This is the change in the dependent variabl
Beta represents the standardised regression coefficient.
The proportion of variability in the pain tolerance threshold that may be explained
using R2.
When the Bonferroni adjustment for multiple testing was applied, p<0.008 for therm
as significant.[18], this is the first study in humans to suggest such a
relationship.
In our study we found associations between the opioid
receptor genes and thermal and muscle pressure pain
but not with mechanical visceral pain. It may be that
different opioid receptors have different influences on
discrete pain modalities. The mu-opioid receptor (MOR)
is thought to be involved in perception of thermal and
chemical pain [19,20]. The delta-opioid receptor (DOR)
plays a role in mechanical, neuropathic and inflamma-
tory pain [19,21]. Although the data are controversial,
some authors suggest that the kappa opioid receptor
(KOR) might be involved in mediating visceral pain
[19,22]. In our data, no OPRM SNPs were retained as
independent predictors of pain sensitivity to any of the
pain modalities. Instead, polymorphisms in OPRK were
associated with thermal and mechanical pain. OPRK was
not found to be associated with visceral pain perception.
The functional significance of the OPRK SNPs is
unknown. It is unclear why OPRK rather than OPRM or
OPRD appears to influence pain sensitivity. One possible
mechanism may be through the process of receptor di-
merisation. Opioid receptor subtypes MOR, DOR and
KOR are thought to interact with each other to form
complexes known as receptor dimers, which may have
altered function [23,24]. Therefore genetic variability in
OPRK, the gene coding for KOR, may indirectly influ-
ence the role of MOR or DOR in pain processing. This
is an area of controversy however as more recent data
have suggested that opioid receptors, especially MOR
and DOR, may be distinct in both physical location and
also mode of pain transmission [10].
This is the first study to test and find associations
between experimental pain sensitivity and polymor-
phisms in OPRK. In this study OPRK rs7824175 was
associated with variability in mechanical muscle pain.f inter-individual in pain sensitivity
B (CI) Beta p-value
2.696 (0.987-4.405) 0.482 0.003
2.267 (0.613-3.921) 0.405 0.009
−1.84 (−3.45 ~ −0.22) −2.315 0.027
B (CI) Beta p-value
0.149(0.055 ~ 0.244) 0.514 0.003
0.145 (0.06 ~ 0.23) 0.5 0.002
−0.159(−0.275 ~ −0.044) −0.405 0.009
e associated with a unit change in the predictor variable.
by its association with the factors in the regression model is calculated
al skin pain and p<0.01 for muscle pressure pain were considered
Figure 3 Association between OPRK SNPs and variability in
muscle pressure pain thresholds (univariate analysis). a)
Carriage of the OPRK rs7016778 A allele (genotype AA / AT, n=9,
median 58.8 kPa (range 33.4-76.4)) had higher muscle pressure pain
thresholds than non carriers (genotype TT, n=22, median 38.2 kPa
(range 25.5-59.3)). p=0.008. b) Carriers of the OPRK rs7824175 C allele
(genotype CC / CG, n=4, median 28.2 kPa (range 25.2-37.1)) had
lower pain thresholds than non carriers (genotype GG, n=27, median
40.9 kPa (range 27.0-76.4)), p=0.01. Lines demonstrate median values.
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OPRK rs7824175 and residual pain in a cohort of cancer
patients titrated on oral morphine [25].
The OPRK SNPs which are associated with variation
in pain sensitivity in this study are found in intronic
regions of the gene. Introns are generally not involved in
coding for protein synthesis. The exact role of these
intronic SNPs in opioid response is not yet known. It is
possible that they may influence clinical outcome
through a process known as linkage disequilibrium
(non-random association), whereby these polymor-
phisms may represent markers for true susceptibility
polymorphisms [26] which do alter protein function.
This may explain why SNPs which are not in linkage
disequilibrium together remained significant on multi-
variate testing. Alternatively these intronic SNPs may be
involved in the production of functionally variable opioid
receptor subtypes (isoforms) through the mechanism ofalternative pre-mRNA splicing. Practical challenges of
examining human brain RNA means that most research
into gene expression in this area has been carried out
in vitro using cell lines expressing mu opioid receptors
[27]. There are data however to suggest that genetic
variation at the RNA level does occur. Only one OPRM
gene has been identified yet at least 25 splice variants
from the mouse OPRM gene have been identified and 11
from humans [28]. An intronic SNP, OPRM rs563649
has been associated with altered mRNA levels and trans-
lation efficacy in OPRM isoforms [29]. Alternative spli-
cing for the delta and kappa opioid receptor have also
been detected [30].
It is likely that pain perception is under the control of
a number of different interacting genetic and environmen-
tal influences [31]. Despite minimising the number of
non-genetic confounders by carrying out these analyses in
healthy volunteers, the data presented in this paper
demonstrate that there remain a number of other factors
which are likely to significantly contribute to variability in
pain sensitivity. Gender accounted for approximately 20%
of the variance in thermal pain sensitivity. The finding that
males were able to tolerate higher somatic but not visceral
pain thresholds mirrors other studies [12,32,33]. Hormo-
nal differences, differences in skin thickness between
males and females or neurobiological factors may play a
role [33,34].
Limitations
As with any genetic association study in pain, there are a
number of limitations. This study explored the associa-
tion between opioid receptor genes and experimental
pain sensitivity. It carried out in healthy Caucasian
volunteers, with uncertain relevance to patients with
painful conditions or subjects with different ethnicities.
It is likely that there are many more “pain genes” which
contribute to variability in pain sensitivity, each with a
relatively small effect size. For example, serotonin is a
key signaling molecule in the gastrointestinal tract and is
involved in both pro-nociception and antinociception
[35]. Polymorphisms in genes involved in the seroto-
nergic system such as SLC6A4, which codes for the
serotonin re-uptake transporter, may be influential in
visceral pain perception. Similarly, it is likely that other
non-genetic factors affect nociception. For example,
there is documented association between pain (particu-
larly visceral pain) and psychometric indices such as
anxiety and neuroticism [36-38]. There are also studies
which suggest that sleep, psychological distress and
blood pressure can alter pain perception [39,40]. These
parameters were not measured in this study. Different
experimental pain modalities have been shown to be
poorly correlated, suggesting that they represent different
specific dimensions of pain perception [41]. Therefore it is
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associated with each pain modality, as suggested by our
data. Larger studies are required to test all genes and all
gene-gene and gene-environment interactions.
The power of genetic association studies and thus the
sample size required to detect true associations is depen-
dent on a number of factors including the number of
polymorphisms being tested, the frequency of the sus-
ceptibility allele, the strength of the association and the
complexity of the trait being examined. This study was
specifically designed to minimise the impact of some of
these factors. Accurate phenotype definition has yielded
significant results in relatively small studies previously.
One of the landmark studies of the role of UGT1A1 in
irinotecan toxicity included only 63 patients, of whom
six had the clinical outcome of interest (grade 4 neutro-
penia)[42]. One of the earliest genome wide association
studies was carried out in 146 individuals (96 cases and
50 controls) in which 103,611 SNPs were analysed and a
polymorphism in the gene coding for complement factor
H was found to be significantly associated with advanced
age-related macular degeneration [43]. This phenotype
was later tightened a GWA conducted in 96 cases and 130
controls yielded very significant results (p = 4.1 × 10–12)
which have been subsequently replicated [44]. Pain
perception is a complex trait, genetic variability is likely to
be associated with small or modest effect sizes [45]. In this
study, unlike genetic association studies in patients under-
going painful procedures or patients with cancer pain,
pain stimulation was standardised and reliable, objective
accurate study outcomes were used and the study popula-
tion comprised of otherwise healthy volunteers. Therefore
the number of potential confounding factors and the
complexity of the outcomes being measured were
minimised. In this study SNPs were only included if they
had a minor allele frequency of > 10%. In this study the
genetic associations with muscle pressure pain remained
significant even after conservative correction for multiple
testing. However, a formal pre-study power calculation
was not performed because the patient data were origin-
ally collected for different studies. Therefore the findings
presented in this study must be considered preliminary
and hypothesis generating. These findings need to be
replicated in other studies and larger sample sizes are
undoubtedly required to identify the smaller genetic effect
sizes [46].
Finally, experimental pain stimuli cannot be compared
directly to pain in the clinical settings where hyper-
algesia and a variety of psychosocial variables come into
play. However, the current models have been shown to
be translatable to clinical pain [47,48] and the data
presented here may be used to generate hypotheses
for testing in clinical trials of patients with painful
conditions.Conclusion
Although this is a small study, significant association
between the opioid receptor genes and experimental
pain sensitivity supports the influence of genetic vari-
ability in pain perception. Experimental pain studies in
healthy volunteers provides a platform from which to
explore inter-individual variation in sensitivity to pain,
which is relatively free from confounders that limit stu-
dies in painful disease states. Replication in larger stud-
ies involving patients is necessary to further explore this
association and to examine the clinical significance of
such findings.
Methods
Data were collected from three previously published
experimental pain studies in healthy volunteers. The first
study (Study A) was a comparative study of oxycodone
and morphine in a multi-modal, tissue-differentiated
experimental pain model [49]. The second (Study B) was
a study of analgesic efficacy of peripheral κ-opioid recep-
tor agonist CR665 compared to oxycodone in a multi-
modal, multi-tissue experimental human pain model
[50]. The third (Study C) was a study of different effects
of morphine and oxycodone in experimentally evoked
hyperalgesia [47]. All studies were approved by the local
Ethical Committee (A: VN 2002/143, B: VN-20060021,
C: N-0070025) and The Danish Medicines Agency
(A: 2612–2168, B: 2612–3145, C: 2612–3463).
Each study was a three-arm study, with each subject
receiving placebo, oxycodone and either morphine or
CR665. Therefore each subject underwent baseline pain
sensitivity testing on three occasions, each at least one
week apart. Only these baseline pain data, which were
assessed before administration of placebo and each of
the two study drugs, were included in this study. This
study includes data from pain sensitivity tests which
were performed in at least two out of the three studies.
Thermal skin pain, muscle pressure pain and mechanical
visceral pain were analysed. For each study subject,
details about age and gender were also recorded.
DNA was available for 19 out of 24 subjects from
Study A, 15 out of 18 subjects from Study B and 21 out
of 24 subjects from Study C. One subject from Study B
was excluded due to non-Caucasian ethnicity, in order
to minimise bias due to population stratification in the
genetic association analysis. Four subjects were excluded
from study C as they had already participated in Study B.
Experimental pain sensitivity testing
Thermal skin pain
Thermal skin testing data were used from studies A and C
(total N = 36). A computer-driven heat pain device (TSA-
II NeuroSensory Analyzer, Medoc Ltd, Ramat Yishai,
Israel) was used for the heat stimulation. A thermode with
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of the forearm 10 cm distal from the elbow and the
subjects were asked to press a button when the pain tole-
rance threshold (PTT) was reached i.e. when they could
no longer withstand the pain. The temperature was
increased from 32°C to a maximum at 52°C at a rate of
1°C/s. When the subjects pressed the button, the ther-
mode was cooled to 32°C and the experiment repeated.
Three consecutive measurements were performed and the
average was computed.
Muscle pressure pain
Muscle pressure pain data were used from studies B and
C (total N = 31). The electronic cuff algometer (Aalborg
University, Aalborg, Denmark) consisted of a pneumatic
tourniquet cuff, a computer-controlled air compressor,
and an electronic 10-cm visual analogue scale (VAS).
The compressor (Condor MDR2; JUN-AIR International
A/S, Nørresundby, Denmark) was connected to an
electric-pneumatic converter (ITV2030; SMC Corp.,
Tokyo, Japan) and controlled by a computer through a
data acquisition card (PCI 6024E; National Instruments,
Austin, TX). The pain intensity was recorded continu-
ously on the visual analogue scale (VAS) and sampled at
100-ms intervals. The pneumatic tourniquet cuff was
wrapped tightly around the gastrocnemius muscle. The
cuff was automatically inflated (compression rate 0.50
kPa/s) until the PTT was reached.
Mechanical visceral pain
Mechanical visceral pain data were used from studies A,
B and C (total N = 50). A probe designed for multimodal
stimulation of the oesophagus was used. Before the study
all subjects were instructed how to use the 0–10 electronic
VAS, for the visceral stimulations, where 0 = no percep-
tion and 10 = unbearable pain. In order to induce mecha-
nicaloesophageal pain, the oesophageal bag was distended
at a constant infusion rate until ‘moderate pain’ intensity
ratings (defined in these studies as VAS score of 7) were
reached. The volumes (ml) of distension at this point were
used for further analysis.
Single nucleotide polymorphism (SNP) genotyping
Genotyping for polymorphisms across OPRM, OPRK
and OPRD was carried out using sequence specific pri-
mers and polymerase chain reaction. Five polymorphisms
in OPRM (rs6912029G/T, rs179997A/G, rs56364C/T,
rs9479757G/A, rs533586C/T), eight in OPRK (rs1050415T/
C, rs7836120A/G, rs647379T/C, rs1365098G/T, rs701677T/
A, rs7824175G/C, rs16918875C/T, rs963549G/A) and five
in OPRD (rs1042114G/T, rs533123G/A, rs419335A/G,
rs2236857T/C, rs2234918C/T) were included in the study.
The details of primers are as previously described [25].
Within each of the genes polymorphisms were selected totry to cover allelic diversity across each gene. Polymor-
phisms in regions most likely to have an impact on gene
function were prioritised (promoter region, exons, intron-
exon boundaries, 3-UTR), as were polymorphisms for
which there exists published data.
Linkage disequilibrium between pairs of SNPs was
tested and haplotypes were constructed using the software
programmes PHASE [51] (http://www.stat.washington.
edu/stephens/software.html) and Haploview (Haploview
version 4.0, Broad Institute, Cambridge, USA) [52].
Statistical analysis
All genotype frequencies were tested for Hardy-
Weinberg equilibrium using Chi-square goodness-of-fit
test (Haploview version 4.0, Broad Institute, Cambridge,
USA). Each genetic variant tested was a bi-allelic single
nucleotide polymorphism. The genetic model under
which a genetic variant may be assumed to influence the
pain sensitivity phenotype is unknown. It is not known
whether the variant allele could be a risk-enhancing
allele (increases the likelihood of a poor outcome) or a
protective allele (increases the likelihood of a good out-
come). For this reason allele carriage, frequency of sub-
jects homozygous (AA) + heterozygous (AB) for allele A
versus frequency of subjects homozygous (BB) for allele
B, was used for the genetic association analysis (Table 1).
Reliability between the three baseline scores for each
patient was tested using Cronbach’s α. Values >0.7 were
considered to be indicative of reliability. The average of
the three baseline pain sensitivity scores were used as
the outcome variables in the genetic association study.
A number of statistical methods for examining gene-
gene and gene-environment interactions have been pro-
posed including regression, classification and regression
trees, neural networking, combinatorial partitioning and
multifactor dimensionality reduction [53]. In this study
multivariate linear regression was used to investigate the
joint effect of the predictor variables (clinical and
genetic) on the experimental pain thresholds (dependent
variables).
Univariate analyses were carried out to screen for an
association between individual clinical (gender and age)
and genetic predictor variables and the outcome variables
(average pain sensitivity scores). Normally distributed
continuous variables (thermal skin pain and mechanical
visceral pain) were analyzed using t-tests and non-
parametric data (muscle pressure pain) were analysed
using Man-Whitney U test. Factors with p<0.1 on univari-
ate analysis (Table 2) were included in the multivariate
modelling. Variables with p>0.1 were excluded in order to
reduce the number of predictor variables. Variable selec-
tion was carried out using a stepwise method. Only factors
with p<0.05 were retained in the final model. Non-
parametric outcome data (i.e. muscle pressure pain) were
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Bonferroni adjustment for multiple testing was applied,
dependent on the number of factors included in the final
modelling [54].
Statistical analysis and plots were performed using
PASW 18 for Windows (SPSS, Chicago, IL) and GraphPad
version 4.02 for Windows (GraphPad Software, San Diego
California USA).
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